It has been a banner year for biotech buyouts, and these are two of the prime targets.

Pharmaceutical stocks can be excellent defensive investments during times of economic uncertainty, and many pharma stocks are ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

Ascentage Pharma reported 2024 sales of $134.3M, up 342% YoY, driven by a $100M option payment from Takeda under an exclusive agreement. JP Morgan initiated Ascentage Pharma with an Overweight rating ...

Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

Biotech stocks combine scientific innovation with substantial R&D investment in cutting edge medicine. Biotech sector includes companies focused on gene editing and breakthroughs in rare disease ...

Krystal Biotech (KRYS Quick Quote KRYS - Free Report) reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as Vyjuvek gains traction in the U.S. market ...

Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%. KRYS's robust balance sheet ($823M cash and negligible debt) and ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Stock sales from drug developers are off to a flying start on US exchanges in 2026, boosting the prospects for biotechnology fundraising after turbulence in the sector last year. Aided by a rebound in ...